Geoffrey R. Oxnard

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract 6736: Discovery and characterization of BH-501284: A non-covalent, pan-KRAS inhibitor for treatment of diverse <i>KRAS</i> -mutant tumors.

  Cancer Research · 2026-04-03

• Abstract 5120: Design and discovery of BH-501242, a novel pan-KRAS on/off inhibitor targeting KRAS switch II pocket

  Cancer Research · 2026-04-03

• Abstract 5872: CLK inhibitor BH-30236 synergizes with venetoclax in anti-leukemia activity via splicing modulation in preclinical AML and CLL models

  Cancer Research · 2026-04-03

• Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

  Nature Communications · 2026-03-12 · 1 citations

• EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy

  JCI Insight · 2026-01-22

• Data from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Figure S2 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Table S2 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Figure S8 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Figure S5 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Figure S3 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Figure S7 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Table S1 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Figure S4 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Table S3 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Figure S6 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Supplementary Figure S1 from Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

  2026-01-19

• Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancer

  Clinical & Translational Oncology · 2026-01-03

• Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy

  Journal of Molecular Diagnostics · 2026-01-02

• Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC

  Journal of Thoracic Oncology · 2025-11-29 · 3 citations